ReviewJournal of scleroderma and related disorders2019
Inflammatory arthritis in systemic sclerosis: What to do?
Review in Journal of scleroderma and related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Trial
- Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.Rheumatology international · 2021Trial
- Autoantibody Profiles and Clinical Correlations in Systemic Sclerosis: A Cross-Sectional Study.EJIFCC · 2026Article
- Combination therapy with mycophenolate mofetil, nintedanib, and tocilizumab in a patient with progressive systemic sclerosis-associated interstitial lung disease : A case report and a literature review.Zeitschrift fur Rheumatologie · 2026Review
- Temporomandibular joint disorders in patients with systemic sclerosis: a cross-sectional study.BMC rheumatology · 2026Article
- Chloroquine and hydroxychloroquine: Immunomodulatory effects in autoimmune diseases.World journal of biological chemistry · 2025Review
- Musculoskeletal involvement in systemic sclerosis.Reumatologia · 2024Review
- Scleroderma Associated With Organising Pneumonia and Polyarthritis: A Report of a Rare Case.Cureus · 2024Article
- Increased rate of complications following total knee arthroplasty in patients with systemic sclerosis.International orthopaedics · 2023Article
- Successful Use of Tofacitinib in Scleroderma Arthropathy.Mediterranean journal of rheumatology · 2023Article
- Methods of assessment of joint involvement in various systemic connective tissue diseases.Reumatologia · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Musculoskeletal involvement, including arthritis and tendinopathy, is a common and important determinant of disability and impaired quality of life in systemic sclerosis. However, the treatment of arthritis in systemic sclerosis has not been studied as a primary outcome in randomized controlled trials, and arthritis-specific outcome measures for systemic sclerosis have not been sufficiently validated to date. Rheumatologists caring for patients with systemic sclerosis must address these complaints regularly despite the fact that the level of evidence for the treatment of systemic sclerosis-related inflammatory arthritis is limited. Consensus statements, based on treatments for related musculoskeletal aspects of rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune diseases, support the use of methotrexate and hydroxychloroquine. Newer biologics, which have efficacy in the treatment of other autoimmune conditions, may show promise in the treatment of arthritis in systemic sclerosis. In this article, we review the current literature on the assessment and treatment of systemic sclerosis arthritis in order to address management considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.